Table 1 Base case and sensitivity analysis by geographic area (SA includes only studies with birth prevalence measure) (detection rate per 100,000 newborns)
Base case | Sensitivity analysis (birth prevalence) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MMA | Isolated MMA | MMA | Isolated MMA | |||||||||
Region | point estimate (95% CI) | Number of studies | I2 | point estimate (95% CI) | Number of studies | I2 | point estimate (95% CI) | Number of studies | I2 | point estimate (95% CI) | Number of studies | I2 |
North America | 1.22 (0.61–2.01) | 10 | 79.79% | 0.38 (0.09–0.79) | 8 | 53.23% | 1.36 (0.71–2.20) | 9 | 76.46% | 0.42 (0.09–0.91) | 7 | 53.07% |
Europe | 1.12 (0.50–1.91) | 11 | 79.22% | 0.60 (0.16–1.23) | 6 | 2.17% | 1.55 (0.51–3.02) | 9 | 79.95% | 0.60 (0.16–1.23) | 6 | 2.17% |
Asia-Pacific | 0.79 (0.44–1.21) | 12 (15 cohorts) | 45.46% | 0.51 (0.32–0.74) | 9 (12 cohorts) | 0.00% | 1.00 (0.46–1.69) | 11 | 44.76% | 0.57 (0.27–0.96) | 8 | 0.00% |
MENA | 6.04 (4.02–8.41) | 6 | 15.78% | 5.69 (2.54–9.87) | 2 | NA | 5.60 (2.94–8.94) | 5 | 21.45% | NA | NA | NA |